Kazia Therapeutics LTD cash flow statement

In fiscal 2025, Kazia Therapeutics LTD's operations generated −$8.6m of cash; it spent $0 on capital projects, leaving free cash flow of −$8.6m.

Cash flow statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Kazia Therapeutics LTD: cash flow statement, annual
Fiscal year	2016Jun 2016	2017Jun 2017	2018Jun 2018	2021Jun 2021	2022Jun 2022	2023Jun 2023	2024Jun 2024	2025Jun 2025
Cash from operations	−9	−9	−7	−7	−17	−10	−6	−9
Depreciation and amortisation	0	1	1	—	—	—	1	1
Stock-based pay	0	0	0	0	1	1	0	0
Capital spending	0	0	0	0	0	0	0	0
Free cash flow	−9	−9	−7	−7	−17	−10	−6	−9
Free cash flow after stock pay	−9	−9	−7	−7	−18	−11	−7	−9

Free cash flow is cash from operations minus capital spending. Free cash flow after stock pay also subtracts stock-based compensation, a real cost to shareholders that the cash flow statement adds back. Dividends, buybacks and shares issued are cash amounts for the period.

Compare with peers

Head to head: KZIA vs LYEL AIM vs KZIA IBIO vs KZIA

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Kazia Therapeutics LTD's SEC filings (10-K and 10-Q), retrieved November 1, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Kazia Therapeutics LTD.